New Rucaparib Designation, STRIVE Trial, 5-Year Ipilimumab Data, and More

The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.

The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.

With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.

New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.

Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.